文献速递神经肿瘤

胶质母细胞瘤患者的MGMT启动子甲基化:甲基化敏感高分辨率熔解曲线是否优于甲基化敏感聚合酶链反应

MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
PubMed 文献 · J Neurosurg · 2018-05-04

该研究比较了甲基化敏感高分辨率熔解曲线(MS-HRM)与甲基化敏感聚合酶链反应(MS-PCR)检测胶质母细胞瘤(GBM)MGMT启动子甲基化的效能。在6种胶质瘤细胞系中MS-HRM与亚硫酸氢盐测序结果强相关(引物1和2的r分别为0.959和0.960,p<0.01),在75例替莫唑胺治疗的GBM手术样本中MS-HRM对无进展生存期和总生存期的预测优于MS-PCR。作者认为MS-HRM可作为MS-PCR的替代方法用于评估GBM患者预后。

要点

  • 在6种胶质瘤细胞系中,MS-HRM甲基化水平与亚硫酸氢盐测序强相关(引物1 r=0.959,引物2 r=0.960,p<0.01)。
  • 在75例替莫唑胺治疗的GBM患者中,MS-HRM预测无进展生存期(P=0.00023)和总生存期(P=0.00019)均优于MS-PCR(P=0.0035和P=0.00028)。
  • 多因素Cox回归显示MS-HRM对治疗结局的预测显著优于MS-PCR(无进展生存期P=0.001 vs 0.207;总生存期P=0.013 vs 0.135)。

核心结论

  • MS-HRM在检测MGMT启动子甲基化方面优于MS-PCR。
  • 作者建议MS-HRM作为MS-PCR的替代方法用于评估GBM患者的预后。

研究设计与样本

  • 研究制备了覆盖CpG 72–89的3套引物用于MS-HRM分析,以确定6种人胶质瘤细胞系的甲基化水平,并通过克隆等位基因的亚硫酸氢盐测序验证结果。
  • 研究还对75例接受替莫唑胺治疗的GBM患者的手术样本进行MS-HRM以评估MGMT甲基化状态,并与MS-PCR结果比较,采用受试者工作特征(ROC)曲线、单因素和多因素分析。

主要发现

  • 6种胶质瘤细胞系中MS-HRM与亚硫酸氢盐测序的甲基化水平强相关,引物1和2的相关系数分别为r=0.959和r=0.960(p<0.01)。
  • 基于log-rank分析,MS-HRM在根据MGMT启动子甲基化状态预测无进展生存期和总生存期方面显著优于MS-PCR(MS-HRM与MS-PCR预测无进展生存期的P值分别为0.00023和0.0035;预测总生存期的P值分别为0.00019和0.00028)。
  • ROC分析显示MS-HRM的曲线下面积大于MS-PCR(无进展生存期:0.723 vs 0.635;总生存期:0.716 vs 0.695)。
  • 多因素Cox回归分析显示MS-HRM对治疗结局的预测显著优于MS-PCR(MS-HRM vs MS-PCR:无进展生存期,p=0.001 vs 0.207;总生存期,p=0.013 vs 0.135)。

关键数值与推荐

  • MS-HRM引物1和2与亚硫酸氢盐测序的相关系数分别为r=0.959和r=0.960(p<0.01)。
  • MS-HRM与MS-PCR预测无进展生存期的log-rank P值分别为0.00023和0.0035,预测总生存期的P值分别为0.00019和0.00028。
  • MS-HRM与MS-PCR的ROC曲线下面积:无进展生存期0.723 vs 0.635;总生存期0.716 vs 0.695。
  • 多因素Cox回归中MS-HRM与MS-PCR的P值:无进展生存期p=0.001 vs 0.207;总生存期p=0.013 vs 0.135。

临床怎么用

  • 作者建议MS-HRM作为MS-PCR的替代方法用于评估GBM患者的预后。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The methylation status of the O6-methylguanine-DNA methyltransferase (MGMT) gene promoter is a prognostic factor in adults with glioblastoma (GBM); it also yields information that is useful for clinical decision-making in elderly GBM patients. While pyrosequencing is the gold standard for the evaluation of the methylation status of MGMT, methylation-sensitive polymerase chain reaction (MS-PCR) assay continues to be used widely. Although MS-PCR results exhibited a good correlation with the prognosis of patients with GBM treated under the Stupp protocol, interpretation of the bands is based on subjective judgment, and the assay cannot be used to analyze heterogeneously methylated samples. We assessed whether methylation-sensitive high-resolution melting (MS-HRM) is an alternative to MS-PCR. METHODS: The authors prepared 3 primer sets that covered CpG 72–89 for MS-HRM analysis to determine the methylation levels of 6 human glioma cell lines. The results were validated by bisulfite sequencing of cloned alleles. The authors also subjected surgical samples from 75 GBM patients treated with temozolomide (TMZ) to MS-HRM to assess the MGMT methylation status and compared the findings with MS-PCR results using receiver operating characteristic (ROC), univariate, and multivariate analyses. RESULTS: There was a strong correlation between the methylation levels of the 6 glioma cell lines evaluated by MSHRM and by bisulfite sequencing; with primers 1 and 2, the correlation was significant (r = 0.959 and r = 0.960, respectively, p < 0.01). Based on log-rank analysis, MS-HRM was significantly better than MS-PCR for predicting progressionfree survival (PFS) and overall survival (OS) based on the methylation status of the MGMT promoter (PFS predicted by MS-HRM and MS-PCR = 0.00023 and 0.0035, respectively; OS = 0.00019 and 0.00028, respectively). ROC analysis showed that the area under the curve was larger with MS-HRM than with MS-PCR (PFS: 0.723 vs 0.635; OS: 0.716 vs 0.695). Based on multivariate Cox regression analysis, MS-HRM was significantly better than MS-PCR for predicting the treatment outcome (MS-HRM vs MS-PCR: PFS, p = 0.001 vs 0.207; OS, p = 0.013 vs 0.135). CONCLUSIONS: The authors’ findings show that MS-HRM is superior to MS-PCR for the detection of MGMT promoter methylation. They suggest MS-HRM as an alternative to MS-PCR for assessing the prognosis of patients with GBM.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Yamashita S, Yokogami K, Matsumoto F, et al. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay? J Neurosurg. 2018. PMID: 29726772. doi:10.3171/2017.11.JNS171710

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。